Protocol Ledger

NCT05225675 · Phase II · COMPLETED

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy

Interventional Phase II clinical trial protocol NCT05225675 sponsored by argenx in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-31 Enrollment: 54 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05225675
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)54 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05225675
Protocol FieldVerified Registry Value
NCT IdentifierNCT05225675
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment54 participants (ACTUAL)
Registered Start Date2022-03-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05225675
Hospital Research SiteLocationSite Profile
University of Kansas Medical CenterKansas City, KSOpen Hospital Dossier ->
University of North Carolina at Chapel HillChapel Hill, NCOpen Hospital Dossier ->
Cleveland ClinicCleveland, OHOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI